Business
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo
About this update from Lisata Therapeutics, Inc.
[{"type":"image","alt":"Lisata Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Lisata Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y4XbqVAm8oIdeBK9.mjRkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363","width":300,"height":84}},"lazy":false},{"type":"text","content":"Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025","length":174,"tagName":"p"},{"type":"text","content":"Cash runway extending into the third quarter of 2026 with no debt","length":65,"tagName":"p"},{"type":"text","content":"Conference call scheduled for today at 4:30 p.m. Eastern Time","length":61,"tagName":"p"},{"type":"text","content":"BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2025.","length":367,"tagName":"p"},{"type":"text","content":"“Lisata maintains momentum into 2025 despite a challenging market for small cap healthcare companies as we continue to make notable progress in both our clinical development portfolio and partnering initiatives,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. “Overall, our focus remains on evaluating certepetide in multiple clinical and preclinical studies across a variety of solid tumors and non-cancer indications. In January, positive results stemming from both Cohort A of the ASCEND trial as well as the iLSTA trial were presented at ASCO-GI and we maintain our forecast of a data-rich period for the remainder of 2025 and into 2026. Heading the list of anticipated results are those from Cohort B of the ASCEND trial as well as results from Catalent’s preclinical evaluation combining certepetide with their SMARTag® antibody-drug conjugate (ADC) platform.”","length":898,"tagName":"p"},{"type":"text"...